Shari Damast, MD

• Alessandro Santin
• Gloria Huang
• Henry S. Park
• Jonathan Leventhal
• Masoud Azodi
• Mitchell Clark
• Natalia Buza
• Pei Hui
• Suzanne B. Evans
• Zhe Jay Chen

Brachytherapy; Radiotherapy

• Investigating the Relationship between the Dose to the Recto-Vaginal Reference Point and Vaginal Stenosis among Cervical Cancer Patients Treated at a North American Academic InstitutionAdefres B, Wallington D, Tien C, Damast S. Investigating the Relationship between the Dose to the Recto-Vaginal Reference Point and Vaginal Stenosis among Cervical Cancer Patients Treated at a North American Academic Institution. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e501. DOI: 10.1016/j.ijrobp.2023.06.1746.
• Prognostic Impact of Mismatch Repair Deficiency on Stage I-II Endometrioid Endometrial Cancer Treated with Adjuvant Radiation Therapy: A Multi-Institutional AnalysisSherwani Z, Alegun J, Russo A, Damast S, Albuquerque K, Nwachukwu C, Dyer M, Fields E, Beriwal S, Horne Z, Vergalasova I, Ohri N, Taunk N, Chino J, Kidd E, Leung E, Song J, Hathout L. Prognostic Impact of Mismatch Repair Deficiency on Stage I-II Endometrioid Endometrial Cancer Treated with Adjuvant Radiation Therapy: A Multi-Institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s8. DOI: 10.1016/j.ijrobp.2023.06.217.
• PO38 Clinical Outcomes Following Brachytherapy for Endometrial Cancer Patients with Narrow Vaginal AnatomyAdefres B, Tien C, Damast S. PO38 Clinical Outcomes Following Brachytherapy for Endometrial Cancer Patients with Narrow Vaginal Anatomy. Brachytherapy 2023, 22: s84-s85. DOI: 10.1016/j.brachy.2023.06.139.
• Recent Key Studies in Cancers of the Uterine Corpus and Cervix: New Updates in Immunotherapy, the Microbiome, Bone Density, Quantifying Lymphovascular Invasion, and Hypofractionated Pelvic Radiation Therapy.Harkenrider M, Fields E, Chopra S, Damast S, Kidd E, Chino J. Recent Key Studies in Cancers of the Uterine Corpus and Cervix: New Updates in Immunotherapy, the Microbiome, Bone Density, Quantifying Lymphovascular Invasion, and Hypofractionated Pelvic Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 115: 269-275. PMID: 36621226, DOI: 10.1016/j.ijrobp.2022.07.1833.
• Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Chu C, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Giuntoli R, Han E, Holmes J, Howitt B, Lea J, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington S, Wyse E, Zanotti K, McMillian N, Aggarwal S. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 181-209. PMID: 36791750, DOI: 10.6004/jnccn.2023.0006.
• The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial CarcinomaPatrich T, Wang Y, Elshaikh M, Zhu S, Damast S, Li J, Fields E, Beriwal S, Keller A, Kidd E, Usoz M, Jolly S, Jaworski E, Leung E, Taunk N, Chino J, Russo A, Lea J, Lee L, Albuquerque K, Hathout L. The Impact of Racial Disparities on Outcome in Patients With Stage IIIC Endometrial Carcinoma. American Journal Of Clinical Oncology 2023, 46: 114-120. PMID: 36625449, DOI: 10.1097/coc.0000000000000975.
• Brachytherapy impacts on sexual function: An integrative review of the literature focusing on cervical cancerChin C, Damast S. Brachytherapy impacts on sexual function: An integrative review of the literature focusing on cervical cancer. Brachytherapy 2022, 22: 30-46. PMID: 36567175, DOI: 10.1016/j.brachy.2022.10.012.
• Implementing a simulation-based curriculum for hybrid intracavitary/interstitial brachytherapy using a new, commercially available, US/MR/CT-compatible gynecologic phantomLi J, Tien C, Kassick M, Peters G, Damast S. Implementing a simulation-based curriculum for hybrid intracavitary/interstitial brachytherapy using a new, commercially available, US/MR/CT-compatible gynecologic phantom. Brachytherapy 2022, 22: 157-165. PMID: 36528476, DOI: 10.1016/j.brachy.2022.11.006.
• Racial Disparities in Patients with Stage IIIC Endometrial CancerPatrich T, Wang Y, Elshaikh M, Zhu S, Damast S, Li J, Fields E, Beriwal S, Keller A, Kidd E, Usoz M, Jolly S, Jaworski E, Leung E, Donovan E, Taunk N, Chino J, Russo A, Lea J, Lee L, Albuquerque K, Hathout L. Racial Disparities in Patients with Stage IIIC Endometrial Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e273-e274. DOI: 10.1016/j.ijrobp.2022.07.1283.
• Radiation therapy in the definitive management of medically inoperable endometrial cancerChin C, Damast S. Radiation therapy in the definitive management of medically inoperable endometrial cancer. International Journal Of Gynecological Cancer 2022, 32: 323-331. PMID: 35256419, DOI: 10.1136/ijgc-2021-002532.
• An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulvaLi JY, Arkfeld CK, Tymon-Rosario J, Webster E, Schwartz P, Damast S, Menderes G. An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva. Journal Of Gynecologic Oncology 2022, 33: 0. PMID: 34910394, PMCID: PMC8899873, DOI: 10.3802/jgo.2022.33.e13.
• Improving Radiation Therapy for Cervical CancerKidd E, Harkenrider M, Damast S, Fields E, Chopra S, Chino J. Improving Radiation Therapy for Cervical Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: 841-848. PMID: 35190051, DOI: 10.1016/j.ijrobp.2021.12.006.
• Secondary Prevention, Not Secondary Importance: Embracing Survivorship Concerns and HRT After Cervical Cancer Radiation TherapyDamast S, Chino J. Secondary Prevention, Not Secondary Importance: Embracing Survivorship Concerns and HRT After Cervical Cancer Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: 414-416. PMID: 34998535, DOI: 10.1016/j.ijrobp.2021.09.028.
• Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemicDamast S, Tien CJ, Young M, Altwerger G, Ratner E. Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic. Journal Of Contemporary Brachytherapy 2022, 14: 66-71. PMID: 35233237, PMCID: PMC8867238, DOI: 10.5114/jcb.2022.113058.
• Dosimetric study of Varian Universal Multi-Channel Cylinder System for High-Dose-Rate 192Ir BrachytherapyTien CJ, Damast S, Chen ZJ. Dosimetric study of Varian Universal Multi-Channel Cylinder System for High-Dose-Rate 192Ir Brachytherapy. Brachytherapy 2022, 21: 244-254. PMID: 34996715, DOI: 10.1016/j.brachy.2021.11.001.
• A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instabilityBellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.
• Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma?Yoon J, Fitzgerald H, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ, Hathout L. Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma? Practical Radiation Oncology 2021, 12: e123-e134. PMID: 34822999, DOI: 10.1016/j.prro.2021.10.002.
• Declining Use of Inguinofemoral Lymphadenectomy in the Treatment of Clinically Negative, Pathologic Node Positive Vulvar Cancer: A National Cancer Database AnalysisMokhtech M, Gao S, Kassick M, Menderes G, Damast S. Declining Use of Inguinofemoral Lymphadenectomy in the Treatment of Clinically Negative, Pathologic Node Positive Vulvar Cancer: A National Cancer Database Analysis. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e636-e637. DOI: 10.1016/j.ijrobp.2021.07.1687.
• Reports From Four International Clinical Trials for Cancers of the Cervix, Uterus and Vulva, and a New Guideline for Cervical CancerDamast S, Fields E, Kidd E, Harkenrider M, Chopra S, Chino J. Reports From Four International Clinical Trials for Cancers of the Cervix, Uterus and Vulva, and a New Guideline for Cervical Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 299-306. PMID: 34473967, DOI: 10.1016/j.ijrobp.2021.05.002.
• Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapyLi JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.
• NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Diver E, Fisher CM, Frederick P, Gaffney DK, George S, Giuntoli R, Han E, Howitt B, Huh WK, Lea J, Mariani A, Mutch D, Nekhlyudov L, Podoll M, Remmenga SW, Reynolds RK, Salani R, Sisodia R, Soliman P, Tanner E, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Motter AD. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 888-895. PMID: 34416706, DOI: 10.6004/jnccn.2021.0038.
• Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast CancerLaird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.
• A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals Of Oncology 2021, 32: 1045-1046. PMID: 33932502, PMCID: PMC9465821, DOI: 10.1016/j.annonc.2021.04.013.
• A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial CancerHathout L, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 110: 1423-1431. PMID: 33677053, DOI: 10.1016/j.ijrobp.2021.02.055.
• Benefits of a Multidisciplinary Women’s Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic RadiotherapyLi JY, D’Addario J, Tymon-Rosario J, Menderes G, Young MR, Johung K, Ratner E, Minkin MJ, Damast S. Benefits of a Multidisciplinary Women’s Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy. American Journal Of Clinical Oncology 2021, 44: 143-149. PMID: 33755031, DOI: 10.1097/coc.0000000000000800.
• Feasibility of deploying a U.S. simulation-based gynecological brachytherapy educational workshop to an international settingDamast S, Felder S, Fields E, Singer L. Feasibility of deploying a U.S. simulation-based gynecological brachytherapy educational workshop to an international setting. Brachytherapy 2020, 19: 777-782. PMID: 33221261, DOI: 10.1016/j.brachy.2020.09.015.
• Radiation for Cancers of the Uterine Corpus and Cervix: Incremental Steps, and Glimmers of the FutureChino J, Damast S, Kidd E, Harkenrider M, Albuquerque K, Kamrava M. Radiation for Cancers of the Uterine Corpus and Cervix: Incremental Steps, and Glimmers of the Future. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: 839-845. PMID: 33069345, DOI: 10.1016/j.ijrobp.2020.06.012.
• Does Sequencing of Adjuvant Therapy Influence Outcome for Stage IIIC Endometrial Carcinoma? A Multi-institutional AnalysisHathout L, Wang Y, Elshaikh M, Dimitrova I, Damast S, Li J, Fields E, Beriwal S, Keller A, Kidd E, Usoz M, Jolly S, Jaworski E, Leung E, Donovan E, Taunk N, Russo A, Lea J, Albuquerque K, Lee L. Does Sequencing of Adjuvant Therapy Influence Outcome for Stage IIIC Endometrial Carcinoma? A Multi-institutional Analysis. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: s50-s51. DOI: 10.1016/j.ijrobp.2020.07.2169.
• Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort studyErickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology 2020, 159: 17-22. PMID: 32709539, PMCID: PMC7541557, DOI: 10.1016/j.ygyno.2020.07.016.
• Stage III uterine serous carcinoma: modern trends in multimodality treatmentLi JY, Young MR, Huang G, Litkouhi B, Santin A, Schwartz PE, Damast S. Stage III uterine serous carcinoma: modern trends in multimodality treatment. Journal Of Gynecologic Oncology 2020, 31: e53. PMID: 32266802, PMCID: PMC7286763, DOI: 10.3802/jgo.2020.31.e53.
• NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 660-666. PMID: 32502976, DOI: 10.6004/jnccn.2020.0027.
• Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapyHochreiter A, Kelly JR, Young MR, Litkouhi B, Black JD, Stromberger C, Higgins S, Schwartz PE, Damast S. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy. International Journal Of Gynecological Cancer 2019, 30: 48. PMID: 31722964, DOI: 10.1136/ijgc-2019-000675.
• Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Wyse E, McMillian NR, Scavone J. Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2019, 17: 1374-1391. PMID: 31693991, DOI: 10.6004/jnccn.2019.0053.
• Stage III Uterine Serous Carcinoma: Improved Outcomes in the Modern Era with Multi-Modality TreatmentLi J, Young M, Huang G, Litkouhi B, Santin A, Schwartz P, Damast S. Stage III Uterine Serous Carcinoma: Improved Outcomes in the Modern Era with Multi-Modality Treatment. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s225. DOI: 10.1016/j.ijrobp.2019.06.318.
• Development of a Multi-Institutional Simulation-Based Gynecologic Brachytherapy CurriculumSinger L, Damast S, Lin L, Taunk N, Lee LJ, Albuquerque K, Chino J, Petereit D, Joyner M, Fields E. Development of a Multi-Institutional Simulation-Based Gynecologic Brachytherapy Curriculum. International Journal Of Radiation Oncology • Biology • Physics 2019, 104: 1175-1176. PMID: 31327414, DOI: 10.1016/j.ijrobp.2019.05.023.
• Literature Review of Vaginal Stenosis and Dilator Use in Radiation OncologyDamast S, Jeffery DD, Son CH, Hasan Y, Carter J, Lindau ST, Jhingran A. Literature Review of Vaginal Stenosis and Dilator Use in Radiation Oncology. Practical Radiation Oncology 2019, 9: 479-491. PMID: 31302301, PMCID: PMC7944435, DOI: 10.1016/j.prro.2019.07.001.
• Outcomes of FIGO 2009 stage IB grade 2 or 3 endometrioid endometrial adenocarcinoma treated with adjuvant vaginal brachytherapy following comprehensive surgical stagingHochreiter A, Kelly J, Young M, Litkouhi B, Black J, Stromberger C, Higgins S, Schwartz P, Damast S. Outcomes of FIGO 2009 stage IB grade 2 or 3 endometrioid endometrial adenocarcinoma treated with adjuvant vaginal brachytherapy following comprehensive surgical staging. Gynecologic Oncology 2019, 154: 287. DOI: 10.1016/j.ygyno.2019.04.674.
• Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2019, 17: 64-84. PMID: 30659131, DOI: 10.6004/jnccn.2019.0001.
• Predictors of Pelvic Recurrence in Stage IB Grade 2-3 Endometrioid Endometrial Adenocarcinoma Treated with Post-Operative Vaginal BrachytherapyYoung M, Stahl J, Black J, Litkouhi B, Damast S. Predictors of Pelvic Recurrence in Stage IB Grade 2-3 Endometrioid Endometrial Adenocarcinoma Treated with Post-Operative Vaginal Brachytherapy. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e656-e657. DOI: 10.1016/j.ijrobp.2018.07.1780.
• Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapyStahl JM, Qian JM, Tien CJ, Carlson DJ, Chen Z, Ratner ES, Park HS, Damast S. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. Supportive Care In Cancer 2018, 27: 1425-1433. PMID: 30187220, DOI: 10.1007/s00520-018-4441-5.
• Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2018, 16: 170-199. PMID: 29439178, DOI: 10.6004/jnccn.2018.0006.
• Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinomaStahl JM, Damast S, Bledsoe TJ, An Y, Verma V, Yu JB, Young MR, Lester-Coll NH. Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma. Brachytherapy 2017, 17: 399-406. PMID: 29275078, DOI: 10.1016/j.brachy.2017.11.012.
• Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario GuidelineCarter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, Diefenbach MA, DuHamel K, Florendo J, Ganz PA, Goldfarb S, Hallmeyer S, Kushner DM, Rowland JH. Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. Journal Of Clinical Oncology 2017, 36: jco.2017.75.899. PMID: 29227723, DOI: 10.1200/jco.2017.75.8995.
• Adjuvant Therapy Use and Survival in Stage II Endometrial CancerLester-Coll NH, Young MR, Park HS, Ratner ES, Litkouhi B, Damast S. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer. International Journal Of Gynecological Cancer 2017, 27: 1904-1911. PMID: 28763364, DOI: 10.1097/igc.0000000000001095.
• Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancerQian JM, Stahl JM, Young MR, Ratner E, Damast S. Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer. Journal Of Gynecologic Oncology 2017, 28: 0. PMID: 29027402, PMCID: PMC5641534, DOI: 10.3802/jgo.2017.28.e84.
• Cost-Effectiveness of Adjuvant Intravaginal Brachytherapy in High-Intermediate Risk Early Stage Endometrial CarcinomaStahl J, Lester-Coll N, Bledsoe T, An Y, Damast S. Cost-Effectiveness of Adjuvant Intravaginal Brachytherapy in High-Intermediate Risk Early Stage Endometrial Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e416. DOI: 10.1016/j.ijrobp.2017.06.1597.
• A Novel Tapered Applicator for Vaginal High Dose Rate BrachytherapyMahal A, Geneser S, Yu J, Damast S. A Novel Tapered Applicator for Vaginal High Dose Rate Brachytherapy. Brachytherapy 2017, 16: s101-s102. DOI: 10.1016/j.brachy.2017.04.195.
• Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case reviewDamast S, Takiar V, McCarthy S, Higgins SA. Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review. Gynecologic Oncology Reports 2016, 17: 89-92. PMID: 27536721, PMCID: PMC4975702, DOI: 10.1016/j.gore.2016.08.002.
• Influence of robotic-assisted laparoscopic hysterectomy on vaginal cuff healing and brachytherapy initiation in endometrial carcinoma patientsStahl JM, Park HS, Silasi DA, Azodi M, Damast S. Influence of robotic-assisted laparoscopic hysterectomy on vaginal cuff healing and brachytherapy initiation in endometrial carcinoma patients. Practical Radiation Oncology 2016, 6: 226-232. PMID: 27364883, DOI: 10.1016/j.prro.2015.09.015.
• Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data BaseLester-Coll NH, Park HS, Rutter CE, Corso CD, Young MR, Ratner ES, Litkouhi B, Decker RH, Yu JB, Damast S. Who benefits from chemoradiation in stage III–IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecologic Oncology 2016, 142: 54-61. PMID: 27151429, DOI: 10.1016/j.ygyno.2016.04.544.
• Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic CancerGressel GM, Lundsberg LS, Altwerger G, Katchi T, Azodi M, Schwartz PE, Ratner ES, Damast S. Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer. International Journal Of Gynecological Cancer 2015, 25: 1711-1716. PMID: 26332394, PMCID: PMC4623851, DOI: 10.1097/igc.0000000000000554.
• Influence of Robotic Hysterectomy on Delayed Vaginal Cuff Healing and Brachytherapy Initiation in Endometrial Carcinoma PatientsStahl J, Park H, Damast S. Influence of Robotic Hysterectomy on Delayed Vaginal Cuff Healing and Brachytherapy Initiation in Endometrial Carcinoma Patients. International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e256. DOI: 10.1016/j.ijrobp.2015.07.1192.
• Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinomaPark HS, Ratner ES, Lucarelli L, Polizzi S, Higgins SA, Damast S. Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma. Brachytherapy 2015, 14: 464-470. PMID: 25887343, DOI: 10.1016/j.brachy.2015.03.001.
• High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinomaDamast S, Higgins SA, Ratner E, De Leon MC, Mani S, Silasi DA, Azodi M, Santin A, Rutherford T, Schwartz PE. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. Journal Of Contemporary Brachytherapy 2015, 7: 35-40. PMID: 25829935, PMCID: PMC4371058, DOI: 10.5114/jcb.2015.48539.
• Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic CharacteristicsYoung MR, Higgins SA, Ratner E, Yu JB, Mani S, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Damast S. Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic Characteristics. International Journal Of Gynecological Cancer 2014, 25: 431. PMID: 25621409, PMCID: PMC5603450, DOI: 10.1097/igc.0000000000000376.
• Predictors of Vaginal Stenosis Following Intra-vaginal High-Dose-Rate Brachytherapy for Endometrial CarcinomaPark H, Ratner E, Lucarelli L, Polizzi S, Higgins S, Damast S. Predictors of Vaginal Stenosis Following Intra-vaginal High-Dose-Rate Brachytherapy for Endometrial Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s111. DOI: 10.1016/j.ijrobp.2014.05.532.
• Comparative Patient-Centered Outcomes (Health State and Adverse Sexual Symptoms) Between Adjuvant Brachytherapy Versus No Adjuvant Brachytherapy in Early Stage Endometrial CancerDamast S, Alektiar K, Eaton A, Gerber NK, Goldfarb S, Patil S, Jia R, Leitao M, Carter J, Basch E. Comparative Patient-Centered Outcomes (Health State and Adverse Sexual Symptoms) Between Adjuvant Brachytherapy Versus No Adjuvant Brachytherapy in Early Stage Endometrial Cancer. Annals Of Surgical Oncology 2014, 21: 2740-2754. PMID: 24619493, DOI: 10.1245/s10434-014-3562-4.
• Adjuvant Carboplatin/Paclitaxel and Vaginal Brachytherapy for Locally Advanced Endometrial CancerYoung M, Higgins S, Ratner E, Mani S, Evans S, Silasi D, Azodi M, Rutherford T, Schwartz P, Damast S. Adjuvant Carboplatin/Paclitaxel and Vaginal Brachytherapy for Locally Advanced Endometrial Cancer. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s447-s448. DOI: 10.1016/j.ijrobp.2012.07.1186.
• Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I–II papillary serous endometrial cancerKiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I–II papillary serous endometrial cancer. Gynecologic Oncology 2012, 127: 321-325. PMID: 22850412, DOI: 10.1016/j.ygyno.2012.07.112.
• Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early-stage endometrial cancer.Damast S, Alektiar K, Goldfarb S, Gerber N, Eaton A, Patil S, Mosenkis J, Sit L, Rogak L, Leitao M, Carter J, Basch E. Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early-stage endometrial cancer. Journal Of Clinical Oncology 2012, 30: 9104-9104. DOI: 10.1200/jco.2012.30.15_suppl.9104.
• Sexual Functioning Among Endometrial Cancer Patients Treated With Adjuvant High-Dose-Rate Intra-Vaginal Radiation TherapyDamast S, Alektiar KM, Goldfarb S, Eaton A, Patil S, Mosenkis J, Bennett A, Atkinson T, Jewell E, Leitao M, Barakat R, Carter J, Basch E. Sexual Functioning Among Endometrial Cancer Patients Treated With Adjuvant High-Dose-Rate Intra-Vaginal Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: e187-e193. PMID: 22572074, PMCID: PMC5538259, DOI: 10.1016/j.ijrobp.2012.03.030.
• Impact of Dose on Local Failure Rates After Image-Guided Reirradiation of Recurrent Paraspinal MetastasesDamast S, Wright J, Bilsky M, Hsu M, Zhang Z, Lovelock M, Cox B, Zatcky J, Yamada Y. Impact of Dose on Local Failure Rates After Image-Guided Reirradiation of Recurrent Paraspinal Metastases. International Journal Of Radiation Oncology • Biology • Physics 2010, 81: 819-826. PMID: 20888133, DOI: 10.1016/j.ijrobp.2010.06.013.
• Re-irradiation of Recurrent Paraspinal Metastases with Hypofractionated IG-IMRT: Impact of DoseDamast S, Wright J, Hsu M, Zhang Z, Lovelock M, Bilsky M, Yamada Y. Re-irradiation of Recurrent Paraspinal Metastases with Hypofractionated IG-IMRT: Impact of Dose. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s225-s226. DOI: 10.1016/j.ijrobp.2009.07.520.
• Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane EraDamast S, Ho AY, Montgomery L, Fornier MN, Ishill N, Elkin E, Beal K, McCormick B. Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era. International Journal Of Radiation Oncology • Biology • Physics 2009, 77: 1105-1112. PMID: 19879068, DOI: 10.1016/j.ijrobp.2009.06.042.
• Do metallic ports in tissue expanders affect postmastectomy radiation delivery?Damast S, Beal K, Ballangrud Å, Losasso TJ, Cordeiro PG, Disa JJ, Hong L, McCormick BL. Do metallic ports in tissue expanders affect postmastectomy radiation delivery? International Journal Of Radiation Oncology • Biology • Physics 2006, 66: 305-310. PMID: 16904530, DOI: 10.1016/j.ijrobp.2006.05.017.
• Changes in cerebrospinal fluid neurochemistry during pregnancyAltemus M, Fong J, Yang R, Damast S, Luine V, Ferguson D. Changes in cerebrospinal fluid neurochemistry during pregnancy. Biological Psychiatry 2004, 56: 386-392. PMID: 15364035, DOI: 10.1016/j.biopsych.2004.06.002.